JNJ AI Stock Analysis – Buy, Hold, or Avoid?
Johnson & Johnson (JNJ)
Johnson & Johnson remains a fundamentally robust, diversified healthcare leader with steady growth, resilient margins, and a fair-to-premium valuation justified by its defensive qualities. While short-term technicals are neutral and litigation risks persist, the long-term risk/reward profile is attractive for conservative investors seeking stable growth and income. Near-term caution is warranted ahead of earnings, but the overall outlook favors accumulation for long-term portfolios.
Fundamentals
Johnson & Johnson's fundamentals remain robust, anchored by consistent revenue growth and strong profitability. The company has displayed healthy margin expansion and reliable earnings delivery, supporting its reputation as a blue-chip healthcare leader.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
9.08% YoY
Q4 2025
Net Income
49.11% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q4 2025
Net Income Growth YoY
Latest Quarter: Q4 2025
Revenue Per Share Growth YoY
Latest Quarter: Q4 2025
EPS Growth YoY
Latest Quarter: Q4 2025
Book Value Per Share Growth YoY
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.6B | 24.0B | 23.7B | 21.9B | 22.5B | 22.5B | 22.4B | 21.4B |
| Revenue Growth YoY | +9.08% | +6.77% | +5.77% | +2.39% | +5.26% | +5.25% | +4.31% | +2.34% |
| Net Income | 5.1B | 5.2B | 5.5B | 11.0B | 3.4B | 2.7B | 4.7B | 3.3B |
| Net Income Growth YoY | +49.11% | +91.24% | +18.16% | +237.91% | -15.26% | -89.65% | -8.90% | +4886.76% |
| EPS | $2.10 | $2.14 | $2.29 | $4.57 | $1.43 | $1.12 | $1.95 | $1.35 |
| EPS Growth YoY | +46.85% | +91.07% | +17.44% | +238.52% | -14.88% | -89.15% | -1.52% | +4600.00% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.37% | 69.56% | 67.87% | 66.40% | 68.35% | 69.01% | 69.40% | 69.55% |
| Operating Margin | 21.95% | 29.58% | 28.68% | 28.77% | 17.06% | 23.49% | 29.66% | 29.34% |
| Net Margin | 20.83% | 21.47% | 23.32% | 50.24% | 15.24% | 11.99% | 20.88% | 15.22% |
| Return on Equity (ROE) | 6.27% | 6.50% | 7.06% | 14.08% | 4.80% | 3.84% | 6.55% | 4.65% |
| Return on Assets (ROA) | 5.11% | 5.36% | 5.80% | 9.78% | 3.49% | 2.87% | 4.83% | 3.22% |
Technical Analysis
Johnson & Johnson is currently in a technical consolidation phase within an overall advancing uptrend, as indicated by institutional accumulation signals. The price sits just below the 50-day SMA, with weak momentum and no strong trend confirmation, suggesting short-term indecision.
No extreme reading
Mixed signals
Range-bound market
Watching for cross
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Johnson & Johnson's fundamentals remain robust, anchored by consistent revenue growth and strong profitability. The company has displayed healthy margin expansion and reliable earnings delivery, supporting its reputation as a blue-chip healthcare leader.
Latest Earnings
Q4 2025 Earnings (Dec 28, 2025)
Earnings Per Share (EPS)
Actual
$2.46
Estimated
$2.46
Surprise
$0.00
Surprise %
0.00%
Revenue
Actual
$24.56B
Estimated
$24.15B
Surprise
+$416.01M
Surprise %
+1.72%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $2.46 | $2.80 | $2.77 | $2.77 | $2.04 | $2.42 | $2.82 | $2.71 |
| EPS (Estimated) | $2.46 | $2.76 | $2.68 | $2.58 | $1.99 | $2.21 | $2.71 | $2.64 |
| EPS Surprise | +$0.00 | +$0.04 | +$0.09 | +$0.19 | +$0.05 | +$0.21 | +$0.11 | +$0.07 |
| % Diff | +0.0% | +1.4% | +3.4% | +7.4% | +2.5% | +9.5% | +4.1% | +2.7% |
| Revenue | ||||||||
| Revenue (Actual) | $24.56B | $23.99B | $23.74B | $21.89B | $22.52B | $22.47B | $22.45B | $21.38B |
| Revenue (Estimated) | $24.15B | $23.76B | $22.85B | $21.56B | $22.43B | $22.17B | $22.33B | $21.4B |
| Revenue Surprise | +$416.01M | +$237.64M | +$889.03M | +$334.38M | +$88.78M | +$299.19M | +$116.62M | -$17.95M |
| % Diff | +1.7% | +1.0% | +3.9% | +1.6% | +0.4% | +1.3% | +0.5% | -0.1% |
Valuation
Johnson & Johnson (JNJ) presents a valuation profile that is somewhat elevated relative to the broader pharmaceutical industry but remains competitive within its peer group, reflecting its strong market position and consistent growth. The stock shows a solid earnings growth trajectory and robust profitability metrics that underpin a premium valuation. Analyst sentiment is moderately bullish, supported by optimistic growth prospects and positive operational momentum.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q4 2025 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 24.56 | 24.63 | 21.40 | 16.68 | 9.07 | 25.14 | 36.20 | 18.80 |
| Price to Sales | 20.46 | 20.52 | 18.38 | 15.56 | 18.22 | 15.32 | 17.36 | 15.70 |
| Price to Book | 0.00 | 6.18 | 5.56 | 4.71 | 5.11 | 4.83 | 5.56 | 4.93 |
| Enterprise Value to EBITDA | 0.00 | 85.68 | 50.46 | 45.95 | 26.44 | 60.39 | 75.49 | 47.32 |
| Enterprise Value to Revenue | 0.00 | 21.67 | 19.53 | 16.92 | 18.85 | 15.88 | 18.06 | 16.44 |
Sentiment & Analyst Ratings
Johnson & Johnson (JNJ) sentiment is cautiously optimistic with a consensus moderate buy rating. Analysts highlight growth catalysts such as the MedTech product launch and strong dividend history, balanced against headwinds including biosimilar competition and litigation risks. Retail investors show steady interest but with some pre-earnings caution evident in social sentiment.
Analyst Recommendations
Risk Assessment
Johnson & Johnson exhibits a stable financial position with solid liquidity and manageable leverage, but faces notable regulatory and legal challenges, primarily from extensive talcum powder litigation and opioid settlements. Its business remains competitive with a strong product pipeline, though patent expirations and pricing pressures pose risks. Overall, JNJ presents moderate investment risk with resilient cash flows supporting long-term debt sustainability despite these headwinds.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q4 2025
Quick Ratio
Latest Quarter: Q4 2025
Debt-to-Equity
Latest Quarter: Q4 2025
Debt-to-Assets
Latest Quarter: Q4 2025
| Q4 2025 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 0.00 | 1.03 | 1.07 | 1.01 | 1.26 | 1.11 | 1.03 | 1.07 |
| Quick Ratio | 0.77 | 0.77 | 0.80 | 0.76 | 1.03 | 0.86 | 0.79 | 0.85 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.00 | 0.59 | 0.58 | 0.65 | 0.67 | 0.51 | 0.51 | 0.58 |
| Debt-to-Assets | 0.00 | 0.24 | 0.24 | 0.26 | 0.27 | 0.20 | 0.20 | 0.23 |
Liquidity Assessment
Current Ratio: 1.03(Adequate)
Quick Ratio: 0.77(Weak)
The company has relatively weak liquidity and may face challenges meeting short-term obligations.
Solvency Assessment
Debt-to-Equity: 0.59(Moderate)
Debt-to-Assets: 0.24(Low)
The company maintains a balanced capital structure with manageable debt levels.
Frequently Asked Questions about JNJ
AI Answers: Common Questions About JNJ
Get AI-powered answers to the questions investors ask most about Johnson & Johnson
JNJ is a good buy for long-term investors, trading at a P/E of 21.62 and supported by a 28% net margin and >33% ROE. While the stock is near the upper end of its historical valuation range, its robust fundamentals, reliable dividend, and diversified growth justify a premium. Short-term entry may be better timed after the upcoming earnings or a technical breakout above $240.67.
Unless your thesis has changed or you require liquidity, there is no strong reason to sell now. Fundamentals remain strong, and the stock is consolidating rather than breaking down; long-term prospects are intact. However, traders may consider trimming if the stock fails to hold support at $237.90 post-earnings.
The biggest risks are legal liabilities from talcum powder and opioid lawsuits, with contingent liabilities that could impact profitability. Patent expirations and biosimilar competition threaten future drug revenues, while pricing reforms (e.g., Inflation Reduction Act) could pressure margins. Debt and liquidity metrics remain manageable (debt/equity ~0.58, current ratio ~1.03), but ongoing legal and regulatory costs require monitoring.
Technical resistance is at $251.71 (52-week high), with support at $237.90 and stronger floors at $211.68 and $200.63. Analyst price targets have been raised recently, reflecting optimism, but a sustained move above $240.67 with volume is needed for a new uptrend; downside risk is limited unless litigation news worsens.
JNJ is fairly valued at current levels, with a P/E of 21.62 and EV/EBITDA at the upper end of its historical range, reflecting its premium status and stable growth. Its net margin (~28%) and ROE (>33%) justify the premium, though further multiple expansion may be limited without new catalysts.
JNJ's fundamentals are strong: 2025 revenue grew 6.1% YoY, EPS rebounded 89%, gross margin is ~73%, and the company consistently generates high-quality earnings and cash flow. The balance sheet is solid, with moderate leverage and stable liquidity.
Technically, JNJ is consolidating just below the 50-day SMA ($240.67) with neutral RSI (46) and weak trend (ADX <20), suggesting indecision. Key support is at $237.90; a break above $240.67 with volume would be bullish, while a drop below support could see a test of $211.68.
Key catalysts include the April 14, 2026 earnings release, new MedTech product launches, and potential litigation resolutions. Analyst upgrades and dividend increases also support sentiment, while macro events like drug pricing reforms and regulatory changes remain important to monitor.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.